Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Yuta Ushida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3076-8013; OpenAlex author ID A5019986040. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2021: 1 paper · 2022: 4 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  2. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  3. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  4. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. First author DOI 10.1245/s10434-021-10560-7↗
  5. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Co-author DOI 10.1245/s10434-022-11503-6↗
  6. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… Co-author DOI 10.1245/s10434-022-11621-1↗
  7. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  8. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Co-author DOI 10.1016/j.pan.2020.11.026↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu Takahashi · 5 shared papers, 2021–2022 · strength 0.71
  2. Yosuke Inoue · 4 shared papers, 2021–2022 · strength 0.57
  3. Yoshihiro Ono · 4 shared papers, 2021–2022 · strength 0.57
  4. Atsushi Oba · 4 shared papers, 2021–2022 · strength 0.57
  5. Hiromichi Ito · 4 shared papers, 2021–2022 · strength 0.57
  6. Akio Saiura · 4 shared papers, 2021–2022 · strength 0.57
  7. Takashi Sasaki · 3 shared papers, 2022 · strength 0.42
  8. Masato Ozaka · 3 shared papers, 2022 · strength 0.42
  9. Takafumi Mie · 3 shared papers, 2022 · strength 0.42
  10. Naoki Sasahira · 3 shared papers, 2022 · strength 0.42
  11. Genki Watanabe · 1 shared paper, 2022 · strength 0.16
  12. Takeshi Okamoto · 1 shared paper, 2022 · strength 0.13
  13. Tsuyoshi Takeda · 1 shared paper, 2022 · strength 0.13
  14. Akiyoshi Kasuga · 1 shared paper, 2022 · strength 0.13
  15. Yuto Yamada · 1 shared paper, 2022 · strength 0.13
  16. Takaaki Furukawa · 1 shared paper, 2022 · strength 0.13
  17. Masato Matsuyama · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.